Left Heart Disease May Be Associated With Pulmonary Hypertension in Elderly Patients - The Cardiology Advisor

Left Heart Disease May Be Associated With Pulmonary Hypertension in Elderly Patients - The Cardiology Advisor

Left Heart Disease May Be Associated With Pulmonary Hypertension in Elderly Patients - The Cardiology Advisor

Posted: 23 Jun 2020 08:25 AM PDT

Left heart disease (LHD) may be associated with pulmonary hypertension determined by echocardiography, according to a study published in The American Journal of Cardiology.

In this retrospective study, the data of 310 patients ≥ 90 years of age (median age 92 years, 64% women) diagnosed with echocardiographic PH with normal left ventricular systolic function were reviewed using the transthoracic echocardiography database.

Echocardiography was used to determine the type of LHD: left-sided valve disease, left ventricular diastolic dysfunction, or left ventricular hypertrophy. The study's primary outcome was all-cause death 2000 days after diagnosis.

In this cohort, 92% of patients had LHD. All-cause deaths occurred in 49% of the patients during the median follow up of 367 days (interquartile range, 39-1028 days). The following factors were found to be associated with mortality in a multivariable Cox regression analysis after adjusting for age: pericardial effusion (adjusted hazard ratio [aHR, 2.28;  P<.001), right ventricular fraction area change < 35% (aHR, 2.31; P <.001), chronic obstructive pulmonary disease (aHR, 1.93; P =.001), serum albumin < 3.5 g/dL (aHR, 1.76; P =.001), and New York Heart Association class ≥ II (aHR, 1.73; P =.004).

Continue Reading

Limitations of the study include its retrospective nature and the lack of evaluation of the relationship between the severity of comorbidities and PH and prognosis.

"[E]chocardiographic PH in patients ≥ 90 years of age was significantly associated with LHD," concluded the study authors.

Reference

Shimada S, Uno G, Omori T, Radar F, Siegel RJ, Shiota T. Characteristics and prognostic associations of echocardiographic pulmonary hypertension with normal left ventricular systolic function in patients ≥90 years of age (published online May 26, 2020). Am J Cardiol. doi.org/10.1016/j.amjcard.2020.05.031

Topics:

Pulmonary Hypertension Pulmonary Vasculature

Comments

Post a Comment

Popular posts from this blog

Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor

Image
Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Posted: 11 Jul 2019 12:00 AM PDT For patients with severe hypoxemia with pulmonary hypertension or right heart dysfunction, inhaled epoprostenol through high-flow nasal cannula increases oxygenation, according to a study published in Pharmaceutics . The researchers of this retrospective study assessed the effect of inhaled epoprostenol using a high-flow nasal cannula on oxygenation and future mechanical ventilation in patients with hypoxemia comorbid with pulmonary hypertension or right heart dysfunction in an intensive care unit setting. A chart review was completed on adult patients who were admitted into the respiratory care department of the Rush University Medical Center for severe hypoxemia between July 2015 and April 2018 and treated with inha...
Read more

Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News

Image
Novitium&#039;s Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Novitium&#039;s Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Growing Doubt, Uncertainty Over PDE5i Use in Left Heart Disease - Medscape AnMed Health gains national recognition through the Pulmonary Hypertension Association - WSPA.com Novitium&#039;s Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Posted: 12 Jun 2019 05:00 AM PDT The U.S. Food and Drug Administration (FDA) has approved Novitium Pharma 's generic sildenafil for oral suspension at a dose of 10 mg/mL for the treatment of pulmonary arterial hypertension (PAH). This product, which had been designated a competitive generic therapy by the FDA, is the first approved generic equivalent to Pfizer 's Revatio , a vasodilator agent that induces blood ves...
Read more

Analysis: Large pharma companies do little new drug innovation - STAT

Image
Analysis: Large pharma companies do little new drug innovation - STAT Analysis: Large pharma companies do little new drug innovation - STAT Gene Therapy Takes Center Stage at 2019 NORD Summit - Pulmonary Hypertension News People Living With Type 2 Diabetes Want Information and Empathy From Their Doctors More Than New Medications - PRNewswire Analysis: Large pharma companies do little new drug innovation - STAT Posted: 10 Dec 2019 01:51 AM PST L arge pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug development and the discovery of new medicines, and thus lead to a decline in drug innovation. If that argument is credible, there should be evidence to show that the large pharmaceutical companies are responsible for discovering innovative new drugs. To test that claim, we examined the...
Read more